1.64
전일 마감가:
$1.64
열려 있는:
$1.51
하루 거래량:
27,423
Relative Volume:
0.40
시가총액:
$77.26M
수익:
$18.11M
순이익/손실:
$-18.95M
주가수익비율:
-3.7486
EPS:
-0.4375
순현금흐름:
-
1주 성능:
-1.50%
1개월 성능:
-20.00%
6개월 성능:
-27.75%
1년 성능:
-43.45%
에이다진 Stock (ADAG) Company Profile
ADAG을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ADAG
Adagene Inc Adr
|
1.64 | 77.26M | 18.11M | -18.95M | 0 | -0.4375 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
에이다진 Stock (ADAG) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-06-25 | 개시 | China Renaissance | Buy |
2021-03-08 | 개시 | Goldman | Buy |
2021-03-08 | 개시 | Jefferies | Buy |
2021-03-08 | 개시 | Morgan Stanley | Overweight |
에이다진 주식(ADAG)의 최신 뉴스
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com
Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World
Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire
Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq
Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - BERNAMA
Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times
Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan
Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire
Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan
Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat
Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):